MCID: PRT037
MIFTS: 64

Pertussis

Categories: Infectious diseases, Oral diseases, Rare diseases, Respiratory diseases, Smell/Taste diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pertussis

MalaCards integrated aliases for Pertussis:

Name: Pertussis 11 19 58 75 28 2 14 71 75 33
Whooping Cough 11 19 58 75 41 2 14 16 31 33
Bordetella Infections 43 16 71
Bordetella Pertussis Infection 19 33
Bordetella Infection 11 33
Whooping Cough Due to Unspecified Organism 71
Infection Due to Bordetella Parapertussis 33
Whooping Cough Due to B. Parapertussis 33
Whooping Cough, Unspecified Organism 33
Wc - [whooping Cough] 33
Wc - Whooping Cough 11
Tussis Convulsiva 33
Bordetellosis 33

Characteristics:


Prevelance:

Whooping Cough: 1-9/100000 (Europe, Austria, Bulgaria, Estonia, Finland, Croatia, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Portugal, Slovenia, Spain, Sweden, United Kingdom) 1-5/10000 (Belgium, Czech Republic, Denmark, Germany, Netherlands, Norway, Poland, Slovakia) 1-9/1000000 (Cyprus, Greece, Hungary, Malta, Romania) 58

Age Of Onset:

Whooping Cough: All ages 58

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 11 DOID:1116
MeSH 43 D001885
SNOMED-CT 68 26484003
MESH via Orphanet 44 D014917
ICD10 via Orphanet 32 A37.0 A37.1 A37.8 more
UMLS via Orphanet 72 C0043167 C0043168
Orphanet 58 ORPHA1489
UMLS 71 C0006015 C0043167 C0043168

Summaries for Pertussis

MedlinePlus: 41 What is whooping cough? Whooping cough, or pertussis, is a respiratory infection that can cause coughing fits. In serious cases, the coughing can become violent and rapid. You may cough so hard that you vomit. The name of the disease comes from the whooping noise you might make when you try to breathe in after coughing. Whooping cough is very contagious and can affect anyone. But it can be especially serious in babies who did not yet get the vaccine. About half of babies under age one who get whooping cough need care in the hospital. What causes whooping cough? Whooping cough is caused by a type of bacteria called Bordetella pertussis. It spreads from person to person. People who have pertussis usually spread it through coughing, sneezing, or breathing very close to someone. It can also sometimes be spread by touching an infected surface and then touching your nose or mouth. If you get pertussis, you are contagious for about 2 weeks after you start coughing. Antibiotics may shorten the time that you are contagious. What are the symptoms of whooping cough? The symptoms of pertussis usually start within 5 to 10 days after you are exposed. But sometimes you may not get symptoms until up to 3 weeks later. Whooping cough usually starts with cold-like symptoms. They may last for 1 to 2 weeks and can include: Runny nose Mild fever Mild, occasional cough The early symptoms in babies can be different. They may only cough a little bit, or they may not cough at all. Babies may have apnea, which means that there is a pause in breathing. They may start to turn blue. If this happens, get medical care for your baby right away. As whopping cough gets worse, the symptoms may include: Fits of many, rapid coughs followed by a high-pitched "whoop" sound Vomiting during or after coughing fits Exhaustion after coughing fits The coughing fits get worse and start happening more often, especially at night. You may have them for up to 10 weeks or more. Recovery from this can happen slowly. Your cough gets milder and happens less often. The coughing fits can come back if you have another respiratory infection, even months after you first got whooping cough. How is whooping cough diagnosed? Your health care provider may use many tools to diagnose whooping cough: A medical history, which includes asking about your symptoms A physical exam A lab test which involves taking a sample of mucus from the back of the throat through the nose. This may be done with a swab or syringe filled with saline. The sample is tested for the bacteria that causes whooping cough. Blood test Chest x-ray What are the treatments for whooping cough? The treatment for whooping cough is usually antibiotics. Early treatment is very important. It may make your infection less serious and can also help prevent spreading the disease to others. Treatment after you have been sick for 3 weeks or longer may not help. The bacteria are gone from your body by then, even though you usually still have symptoms. This is because the bacteria have already done damage to your body. Whooping cough can sometimes be very serious and require treatment in the hospital. Can whooping cough be prevented? Vaccines are the best way to prevent whooping cough. There are two vaccines in the United States that can help prevent whooping cough: DTaP and Tdap. These vaccines also provide protection against tetanus and diphtheria. Babies and other people at high risk serious disease should be kept away from people who have whooping cough. Sometimes health care providers give antibiotics to family members of people who have had whooping cough or people who have been exposed to it. The antibiotics may prevent them from getting the disease. You may also help prevent the spread of whooping cough (and other respiratory diseases) by: Washing your hands often with soap and water. You can use an alcohol-based hand rub if soap and water are not available. Avoiding touching your face with unwashed hands Cleaning and disinfecting surfaces that you frequently touch, including toys Covering coughs and sneezes with a tissue or upper shirt sleeve, not hands Staying home when sick Avoiding close contact with people who are sick Centers for Disease Control and Prevention

MalaCards based summary: Pertussis, also known as whooping cough, is related to respiratory failure and bronchiolitis, and has symptoms including fever, pruritus and snoring. An important gene associated with Pertussis is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Montelukast and Aluminium phosphate have been mentioned in the context of this disorder. Affiliated tissues include respiratory tract, smooth muscle and dorsal root ganglion, and related phenotypes are homeostasis/metabolism and nervous system

GARD: 19 A rare bacterial infectious disease characterized by severe coughing paroxysms with inspiratory whooping and posttussive vomiting, caused by infection with Bordetella pertussis. After a variable incubation time, the clinical course progresses through a catarrhal stage with sore throat, nasal congestion, rhinorrhea, and mild progressive dry cough, a paroxysmal stage with the typical paroxysmal coughing, and finally convalescence. Disease duration is usually 2-3 months, often with milder presentation in adolescents and adults than in infants and children.

Orphanet: 58 A rare bacterial infectious disease characterized by severe coughing paroxysms with inspiratory whooping and posttussive vomiting, caused by infection with Bordetella pertussis. After a variable incubation time, the clinical course progresses through a catarrhal stage with sore throat, nasal congestion, rhinorrhea, and mild progressive dry cough, a paroxysmal stage with the typical paroxysmal coughing, and finally convalescence. Disease duration is usually 2-3 months, often with milder presentation in adolescents and adults than in infants and children.

CDC: 2 Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Pertussis is known for uncontrollable, violent coughing which often makes it hard to breathe. After cough fits, someone with pertussis often needs to take deep breaths, which result in a "whooping" sound. Pertussis can affect people of all ages, but can be very serious, even deadly, for babies less than a year old. The best way to protect against pertussis is by getting vaccinated

Disease Ontology: 11 A commensal bacterial infectious disease that results in inflammation located in respiratory tract, has material basis in Bordetella pertussis, or has material basis in Bordetella parapertussis, which produce toxins that paralyze the cilia of the respiratory epithelial cells. The infection is characterized by a prolonged, high-pitched, deeply indrawn breath (whoop).

Wikipedia: 75 Whooping cough, also known as pertussis or the 100-day cough, is a highly contagious bacterial disease.... more...

Related Diseases for Pertussis

Diseases related to Pertussis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 648)
# Related Disease Score Top Affiliating Genes
1 respiratory failure 31.1 TLR4 JUN CCL5 CCL2 CCL11
2 bronchiolitis 30.8 TLR4 CCL5 CCL2 CCL11
3 viral infectious disease 30.8 TLR4 CXCR4 CCL5 CCL2
4 pneumonia 30.6 TLR4 CCL5 CCL2 CCL11
5 allergic asthma 30.4 TLR4 ITGB2 CCL5 CCL11
6 otitis media 30.4 TLR4 CCL5 CCL2 CCL11
7 insulin-like growth factor i 30.4 SST MAPK1 EGF AKT1
8 human immunodeficiency virus type 1 30.3 CXCR4 CCL5 CCL2 CCL11
9 neuroblastoma 30.3 SST MAPK1 JUN EGF CXCR4 AKT1
10 bacterial infectious disease 30.2 TLR4 ITGB2 FPR1 CCL2
11 proteasome-associated autoinflammatory syndrome 1 30.2 TLR4 CCL5 CCL2 CCL11
12 bronchial disease 30.2 TLR4 CCL5 CCL2 CCL11
13 pheochromocytoma 30.2 SST MAPK1 JUN EGF ADCY10
14 rapidly involuting congenital hemangioma 30.1 GNAQ GNA14
15 myocarditis 30.1 TLR4 ITGB2 CCL5 CCL2 AKT1
16 toxic encephalopathy 30.0 TLR4 JUN CCL2 AKT1
17 breast adenocarcinoma 30.0 JUN EGF CCL2 AKT1
18 osteogenic sarcoma 30.0 MAPK1 JUN EGF CXCR4 AKT1 ADCY10
19 duodenal ulcer 29.9 TLR4 SST EGF
20 q fever 29.9 TLR4 CCL5 CCL2
21 conjunctivitis 29.9 TLR4 CCL2 CCL11
22 asthma 29.8 TLR4 JUN ITGB2 CXCR4 CCL5 CCL2
23 dermatitis, atopic 29.8 TLR4 CCL5 CCL2 CCL11
24 immune deficiency disease 29.8 JUN ITGB2 CXCR4 CCL5 CCL2 CCL11
25 chronic asthma 29.8 TLR4 CCL5 CCL11
26 respiratory allergy 29.8 TLR4 CCL5 CCL11
27 hyper ige syndrome 29.7 TLR4 FPR1 CCL11
28 arteriosclerosis 29.6 TLR4 CCL5 CCL2 CCL11
29 cystitis 29.6 TLR4 JUN EGF CCL2
30 high grade glioma 29.5 FPR1 EGF CXCR4 AKT1
31 severe acute respiratory syndrome 29.5 TLR4 CCL5 CCL2
32 status epilepticus 29.5 SST JUN ADORA1
33 neutropenia 29.5 TLR4 FPR1 CXCR4 AKT1
34 dilated cardiomyopathy 29.4 TLR4 MAPK1 JUN GNAQ CCL2 AKT1
35 inflammatory bowel disease 29.4 TLR4 SST JUN ITGB2 EGF CCL5
36 hypertension, essential 29.4 TLR4 SST JUN GNAQ EGF CCL5
37 cystic fibrosis 29.4 TLR4 JUN EGF CCL5 CCL2 CCL11
38 peripheral nervous system disease 29.2 TLR4 SST OPRM1 JUN EGF CXCR4
39 eye disease 29.2 TLR4 JUN GNAQ EGF CCL5 CCL2
40 rheumatoid arthritis 29.0 TLR4 MAPK1 JUN ITGB2 GNAQ CXCR4
41 interstitial lung disease 2 29.0 TLR4 JUN EGF CXCR4 CCL5 CCL2
42 diphtheria 11.5
43 tetanus 11.3
44 bordetella parapertussis whooping cough 11.0
45 poliomyelitis 10.9
46 haemophilus influenzae 10.9
47 cholera 10.8
48 measles 10.7
49 hepatitis b 10.6
50 primary agammaglobulinemia 10.6

Graphical network of the top 20 diseases related to Pertussis:



Diseases related to Pertussis

Symptoms & Phenotypes for Pertussis

UMLS symptoms related to Pertussis:


fever; pruritus; snoring; coughing

GenomeRNAi Phenotypes related to Pertussis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 ADCY10 ADORA1 AKT1 CCL11 CCL2 CCL5
2 no effect GR00402-S-2 10.18 ADCY10 AKT1 CCL11 CCL2 CCL5 EGF

MGI Mouse Phenotypes related to Pertussis:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ADCY10 ADORA1 AKT1 CCL2 CXCR4 FPR1
2 nervous system MP:0003631 10.31 ADORA1 AKT1 CCL2 CXCR4 GNAI1 GNAQ
3 normal MP:0002873 10.29 ADORA1 AKT1 CCL11 CCL2 EGF GNA15
4 immune system MP:0005387 10.27 AKT1 CCL11 CCL2 CCL5 CXCR4 EGF
5 growth/size/body region MP:0005378 10.25 ADORA1 AKT1 CCL2 CXCR4 EGF GNA15
6 cardiovascular system MP:0005385 10.14 ADCY10 ADORA1 AKT1 CCL2 CXCR4 GNA15
7 adipose tissue MP:0005375 10.02 AKT1 CCL2 CXCR4 GNAZ OPRM1 SST
8 reproductive system MP:0005389 10 ADCY10 AKT1 CCL2 CXCR4 EGF GNA15
9 respiratory system MP:0005388 9.92 ADORA1 AKT1 CCL11 CXCR4 GNAQ JUN
10 hematopoietic system MP:0005397 9.86 ADORA1 AKT1 CCL11 CCL2 CCL5 CXCR4
11 skeleton MP:0005390 9.85 AKT1 CCL2 CXCR4 GNAI1 GNAQ ITGB2
12 integument MP:0010771 9.44 ADORA1 AKT1 CCL2 CXCR4 EGF GNA15

Drugs & Therapeutics for Pertussis

Drugs for Pertussis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Montelukast Approved Phase 4 158966-92-8 5281040
2
Aluminium phosphate Approved, Investigational Phase 4 7784-30-7
3
Edetate calcium disodium anhydrous Approved, Vet_approved Phase 4 62-33-9, 60-00-4 6049
4
Iron Approved Phase 4 7439-89-6 29936
5
Pentetic acid Approved Phase 4 67-43-6
6 Leukotriene Antagonists Phase 4
7 Hormones Phase 4
8 Anti-Asthmatic Agents Phase 4
9 Hormone Antagonists Phase 4
10 Respiratory System Agents Phase 4
11 Vaccines Phase 4
12 Immunologic Factors Phase 4
13 Adjuvants, Immunologic Phase 4
14 Gastrointestinal Agents Phase 4
15 Antitoxins Phase 4
16 Anti-Ulcer Agents Phase 4
17 Antacids Phase 4
18 Fibrinolytic Agents Phase 4
19 Anticoagulants Phase 4
20 Iron Chelating Agents Phase 4
21 Antidotes Phase 4
22 Protective Agents Phase 4
23 Chelating Agents Phase 4
24 Calcium, Dietary Phase 4
25 Immunoglobulins Phase 4
26 Antibodies Phase 4
27
Calcium Nutraceutical Phase 4 7440-70-2 271
28
Lactitol Approved, Investigational Phase 3 585-86-4 157355
29
Deferiprone Approved Phase 3 30652-11-0 2972
30
Aluminum sulfate Approved Phase 2, Phase 3 10043-01-3
31 Heptavalent Pneumococcal Conjugate Vaccine Phase 3
32 Immunoglobulins, Intravenous Phase 3
33 gamma-Globulins Phase 3
34 Rho(D) Immune Globulin Phase 3
35 Pharmaceutical Solutions Phase 3
36 Cathartics Phase 3
37 Laxatives Phase 3
38 Somatomedin B Phase 3
39 Taxane Phase 3 108169
40 Hemagglutinins Phase 2, Phase 3
41 Agglutinins Phase 2, Phase 3
42 PENTA Phase 3
43
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
44
Azithromycin Approved Phase 2 83905-01-5 447043
45 Monophosphoryl lipid A Phase 1, Phase 2
46 Antibiotics, Antitubercular Phase 2
47
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn 14838-15-4, 492-39-7 131954576 4786 26934
48
Guaifenesin Approved, Investigational, Vet_approved 93-14-1 3516
49
BCG vaccine Approved, Investigational
50
Fluspirilene Approved, Investigational 1841-19-6 3396

Interventional clinical trials:

(show top 50) (show all 327)
# Name Status NCT ID Phase Drugs
1 Optimising the Timing of Whooping Cough Immunisation in MUMs Unknown status NCT03908164 Phase 4
2 The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study Unknown status NCT02771782 Phase 4
3 A Double Blind Randomised Placebo Controlled Trial of Montelukast in the Treatment of Acute Persistent Cough in Young People and Adults in Primary Care Unknown status NCT01279668 Phase 4 Montelukast;Placebo
4 Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults Unknown status NCT02555540 Phase 4
5 An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age Unknown status NCT00870350 Phase 4
6 A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine} Unknown status NCT04056728 Phase 4
7 Safety and Immunogenicity of Adult Formulation Tetanus and Diphtheria Toxoids Adsorbed Combined With Acellular Pertussis (Tdap) Vaccine Following Blood and Morrow Transplantation in Adults Unknown status NCT00336115 Phase 4
8 Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants Unknown status NCT00877357 Phase 4
9 The Efficacy and Safety of Vaccination Against Pertussis. Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
10 Comparison of Two Vaccinal Schemes for DTP-Pertussis-Hib Primo-immunisation in Very Preterm-born Neonates: a Randomised Bicentric Controlled Study Unknown status NCT02179996 Phase 4
11 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Immunogenicity and Safety of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis Vaccine (DTaP) and Measles, Moms and Rubella Vaccine (MMR) Unknown status NCT04638985 Phase 4
12 A Randomized, Controlled, Multicenter Phase 4 Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of Sabin-strain Inactivated Polio Vaccine (sIPV), Diphtheria, Tetanus, Pertussis (DTaP) Vaccine and Live Attenuated Hepatitis A Vaccine (HepA) Unknown status NCT04636827 Phase 4
13 Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents Completed NCT01629589 Phase 4
14 Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose Completed NCT01439165 Phase 4
15 A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. Completed NCT00674908 Phase 4
16 Pertussis Vaccination in Pregnant Women: Implementation and Evaluation of Different Models of Vaccination Dispensation Completed NCT03909126 Phase 4
17 Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) in Persons ≥65 Years of Age Completed NCT00457249 Phase 4
18 Immunogenicity and Safety of Meningococcal (Groups A, C, Y, and W-135) Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Adolescents in the US When Administered Concomitantly With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap Vaccine) Completed NCT00777257 Phase 4
19 Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants Completed NCT01698346 Phase 4
20 Evaluation of GSK Biological's dTpa-IPV Booster Vaccine in Children and Adolescents, 5 Years After Previous dTpa-IPV Boosting. Completed NCT00635128 Phase 4
21 Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T) Completed NCT00802867 Phase 4
22 Immunological Effects of an Acellular Pertussis Booster Vaccination in Children, Young Adults and Elderly With Different Immunisation Background. An International Study in Finland, the Netherlands and the United Kingdom Completed NCT03697798 Phase 4
23 Open Clinical Study to Assess the Immune Response and Safety of a Booster Dose (5th Dose) of a Combination Vaccine Against Diphteria-Tetanus-Pertussis-Polio Given to Healthy Adolescents 15-16 Years of Age. Completed NCT00514059 Phase 4 Boostrix polio
24 Immune Responses in Adults to Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (ADACEL®) 10 Years After a Previous Dose Completed NCT00712959 Phase 4
25 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Adults, Given 10 Years After Previous dTpa Boosting. Completed NCT00548171 Phase 4
26 A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants Completed NCT02145624 Phase 4 Repevax;Boostrix-IPV
27 An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age. Completed NCT01659996 Phase 4
28 An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. Completed NCT00617812 Phase 4
29 Evaluation of GSK Biologicals' dTpa Booster Vaccine in Young Adults 10 Years After Previous dTpa Boosting. Completed NCT00610168 Phase 4
30 Non-specific Effects of Vaccines - In Search of the Immunological Background Completed NCT00168545 Phase 4
31 A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™) Completed NCT02526394 Phase 4 Pertussis containing vaccine
32 Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given as a Booster Dose at 4 to 6 Years of Life in Children Previously Vaccinated With PENTAXIM™ in the Study E2I34 Completed NCT01031303 Phase 4
33 Safety Among Adolescents and Adults of Revaccination With Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) 4 to 5 Years After a Previous Dose Completed NCT00347958 Phase 4
34 Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX® Completed NCT00319553 Phase 4
35 Reactogenicity of Acellular Pertussis Vaccine Booster in Adolescents Who Have Received 5 Prior Doses of BIKEN Acellular Pertussis Vaccine in Combination With Diphtheria and Tetanus Toxoids (TRIPEDIA®) or Who Have Received Primary Vaccination With 3 Doses of Whole-Cell Pertussis Vaccine, Plus at Least 1 Pertussis Booster Vaccination Completed NCT00304265 Phase 4
36 Safety & Immunogenicity of a Booster Dose of dTPa Vaccine (Boostrix®) Co-admnd. With Aventis Pasteur's Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Vaccine (Menactra™) vs Admn. of Either Vaccine Alone in Healthy Adolescents Completed NCT00282295 Phase 4
37 Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand Completed NCT00255021 Phase 4
38 Regulatory Post-Marketing Surveillance (PMS) Study for ADACEL™ (Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined Vaccine for Adult) Completed NCT01137435 Phase 4
39 Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02422264 Phase 4 Prevnar13
40 Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand Completed NCT02408926 Phase 4
41 Regulatory Post-Marketing Surveillance (PMS) Study for TETRAXIM™(Combined Vaccine of Adsorbed Diphtheria, Tetanus, Acellular Pertussis and Enhanced Inactivated Poliomyelitis) Completed NCT01437423 Phase 4
42 A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age Completed NCT01357720 Phase 4
43 Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery Completed NCT02853929 Phase 4
44 Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy Infants Completed NCT02907216 Phase 4
45 Safety and Immunogenicity of Adacel® Vaccine Administered to Persons 10 Years of Age Completed NCT01311557 Phase 4
46 Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China Completed NCT01491087 Phase 4
47 Adacel® (TdaP-Tetanus, Diphtheria, Acellular Pertussis) Booster Vaccination of Acellular Pertussis Vaccine-primed Individuals for Cell Mediated Immunity Assay Development Completed NCT04543669 Phase 4
48 Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child Completed NCT01711645 Phase 4
49 A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot Completed NCT02783170 Phase 4
50 Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants Completed NCT01926015 Phase 4

Search NIH Clinical Center for Pertussis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ERYTHROMYCIN PWDR
Guaifenesin

Cochrane evidence based reviews: bordetella infections

Genetic Tests for Pertussis

Genetic tests related to Pertussis:

# Genetic test Affiliating Genes
1 Pertussis 28

Anatomical Context for Pertussis

Organs/tissues related to Pertussis:

FMA: Respiratory Tract
MalaCards : Smooth Muscle, Dorsal Root Ganglion, Endothelial, Bone Marrow, Neutrophil, Cardiac Myocytes, Pituitary

Publications for Pertussis

Articles related to Pertussis:

(show top 50) (show all 30047)
# Title Authors PMID Year
1
Prior exposure to B. pertussis shapes the mucosal antibody response to acellular pertussis booster vaccination. 62 41
36460655 2022
2
Knowledge and Willingness toward Vaccination among Pregnant Women: Comparison between Pertussis and Influenza. 62 41
36360959 2022
3
Pertussis prevalence among adult patients with acute cough. 62 41
36326303 2022
4
Surveillance on the adverse events following immunization with the pentavalent vaccine in Zhejiang, China. 62
35108152 2022
5
Neuroprotective, Anti-inflammatory Effect of Furanochrome, Visnagin Against Middle Cerebral Ischemia-Induced Rat Model. 62
35819694 2022
6
Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review. 62
34270376 2022
7
Pertussis toxin neutralizing antibody response after an acellular booster vaccination in Dutch and Finnish participants of different age groups. 62
35286231 2022
8
Specialized pro-resolvin mediators induce cell growth and improve wound repair in intestinal epithelial Caco-2 cell cultures. 62
36427427 2022
9
The indirect impact of control measures in COVID-19 pandemic on the incidence of other infectious diseases in China. 62
35722540 2022
10
Historical trends in mortality from "older" vaccine-preventable diseases, Colombia: implications for elimination and control. 62
36423493 2022
11
Common issues and improvement solution of vaccine hesitancy in children with underlying neurological conditions: Experience from one National Children's Medical Center in China. 62
36470687 2022
12
The role of bactericidal and opsonic activity in immunity against Bordetella pertussis. 62
36369768 2022
13
Genetic predisposition to adverse events in Chinese children aged 3-24 months after diphtheria, tetanus, acellular pertussis and haemophilus influenzae type b combined vaccination. 62
36328952 2022
14
Novel approaches to reactivate pertussis immunity. 62
36400443 2022
15
Genomic dissection of the microevolution of Australian epidemic Bordetella pertussis. 62
35543519 2022
16
Diphtheria-tetanus-pertussis (DTP) vaccination: understanding the perspectives and expectations of parents and healthcare professionals in France and India. 62
34435544 2022
17
Experience and attitudes on vaccinations recommended during pregnancy: survey on an Italian sample of women and consultant gynecologists. 62
33956557 2022
18
Maternal immunization: trends in South and Southeast Asian countries. 62
34517746 2022
19
Near-infrared photoimmunotherapy induced tumor cell death enhances tumor dendritic cell migration. 62
35624180 2022
20
The progress of postapproval clinical studies on Sabin IPV. 62
34213408 2022
21
A2A R mediated modulation in IP3 levels altering the [Ca2+]i through cAMP-dependent PKA signalling pathway. 62
36084905 2022
22
Bacterial NadQ (COG4111) is a Nudix-like, ATP-responsive regulator of NAD biosynthesis. 62
36332744 2022
23
Review of scientific evidence to support recommendations of the full-dose DTaP-IPV vaccination in pre-school age children in Italy. 62
36178008 2022
24
Altruistic Vaccination: Insights from Two Focus Group Studies. 62
36454320 2022
25
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6-8, 10-12, and 14-16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study. 62
36164460 2022
26
Conditional probability and ratio-based approaches for mapping the coverage of multi-dose vaccines. 62
36129171 2022
27
Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020). 62
35258415 2022
28
Proteomic characteristics of plasma and blood cells in natural aging rhesus monkeys. 62
36037246 2022
29
Maternal vaccination-current status, challenges, and opportunities. 62
36444417 2022
30
Clinic-level differences in human papillomavirus vaccination rates among rural and urban Oregon primary care clinics. 62
36396353 2022
31
Protecting the Offspring, the Gift of Maternal Immunization: Current Status and Future Perspectives. 62
36423047 2022
32
A high-dimensional cytometry atlas of peripheral blood over the human life span. 62
36218032 2022
33
Knowledge of, and attitudes towards, adult vaccination among General Practitioners in Piedmont, Italy: results from a cross-sectional study. 62
35076653 2022
34
Estimation of vaccine effectiveness using the screening method. 62
36326585 2022
35
Reductions in stillbirths and preterm birth in COVID-19 vaccinated women: a multi-center cohort study of vaccination uptake and perinatal outcomes. 62
36336084 2022
36
Vaccination coverage in Italian children and antimicrobial resistance: an ecological analysis. 62
36352471 2022
37
Non-immunization associated with increased risk of sudden unexpected death in infancy: A national case-control study. 62
36460531 2022
38
Effectiveness of Bacille Calmette-Guerin vaccination policies in reducing infection and mortality of COVID-19: a systematic review. 62
36336688 2022
39
Subnational Gender Inequality and Childhood Immunization: An Ecological Analysis of the Subnational Gender Development Index and DTP Coverage Outcomes across 57 Countries. 62
36423046 2022
40
Vaccination in pregnancy: Healthcare provider attitudes and practices. 62
36352834 2022
41
Use of catch-up vaccinations in the second year of life (2YL) platform to close immunity gaps: A secondary DHS analysis in Pakistan, Philippines, and South Africa. 62
36396512 2022
42
Negative Control Exposures: Causal Effect Identifiability and Use in Probabilistic-bias and Bayesian Analyses With Unmeasured Confounders. 62
35895515 2022
43
Tdap-HPV vaccination bundling in the USA: Trends, predictors, and implications for vaccine series completion. 62
36007751 2022
44
The impact of women's political representation on child health outcomes during 1990-2020: Evidence from a global dataset. 62
36201993 2022
45
A1 Adenosine Receptor Activation Inhibits P2X3 Receptor-Mediated ATP Currents in Rat Dorsal Root Ganglion Neurons. 62
36074232 2022
46
Effect of text message communication on patient presentation for an influenza vaccination in a community-based pharmacy setting. 62
35973934 2022
47
Routine childhood vaccination in India from 2005-2006 to 2015-2016: Temporal trends and geographic variation. 62
36280561 2022
48
Routine Vaccination Coverage - Worldwide, 2021. 62
36327156 2022
49
Spatial distribution, determinants and trends of full vaccination coverage in children aged 12-59 months in Peru: A subanalysis of the Peruvian Demographic and Health Survey. 62
36368757 2022
50
Mapping the distribution of zero-dose children to assess the performance of vaccine delivery strategies and their relationships with measles incidence in Nigeria. 62
36414476 2022

Variations for Pertussis

Expression for Pertussis

Search GEO for disease gene expression data for Pertussis.

Pathways for Pertussis

Pathways related to Pertussis according to GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 TLR4 OPRM1 MAPK1 JUN ITGB2 FPR1
2
Show member pathways
13.91 MAPK1 JUN ITGB2 GNAZ GNAI1 GNA15
3
Show member pathways
13.82 AKT1 CCL11 CCL2 CCL5 CXCR4 EGF
4
Show member pathways
13.77 MAPK1 JUN ITGB2 GNAZ GNAI1 GNA15
5
Show member pathways
13.64 AKT1 CCL11 CCL2 CCL5 CXCR4 GNA14
6
Show member pathways
13.63 MAPK1 GNAZ GNAI1 GNA15 GNA14 EGF
7
Show member pathways
13.57 MAPK1 JUN ITGB2 GNA15 GNA14 EGF
8
Show member pathways
13.55 AKT1 EGF GNAI1 GNAQ GNAZ JUN
9
Show member pathways
13.46 ADORA1 CCL11 CCL2 CCL5 CXCR4 FPR1
10
Show member pathways
13.4 MAPK1 GNAZ GNAI1 GNA15 GNA14 EGF
11
Show member pathways
13.4 OPRM1 MAPK1 JUN ITGB2 FPR1 CCL5
12
Show member pathways
13.38 MAPK1 JUN EGF CXCR4 CCL5 CCL2
13
Show member pathways
13.37 AKT1 EGF GNA14 GNA15 GNAI1 GNAQ
14
Show member pathways
13.34 MAPK1 JUN GNAZ GNAQ GNAI1 GNA15
15
Show member pathways
13.29 AKT1 CCL11 CCL2 CCL5 CXCR4 EGF
16
Show member pathways
13.21 MAPK1 JUN ITGB2 GNAZ GNAI1 GNA15
17
Show member pathways
13.16 AKT1 EGF GNA14 GNA15 GNAI1 GNAZ
18
Show member pathways
13.14 MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
19
Show member pathways
13.14 AKT1 CCL2 EGF GNA14 GNA15 GNAI1
20
Show member pathways
13.11 SST OPRM1 MAPK1 GNAZ GNAQ GNAI1
21
Show member pathways
13.04 GNA14 GNA15 GNAI1 GNAZ ITGB2 JUN
22
Show member pathways
13 MAPK1 JUN GNAZ GNAQ GNAI1 EGF
23 12.99 SST OPRM1 MAPK1 JUN GNAZ GNAQ
24
Show member pathways
12.97 MAPK1 JUN ITGB2 AKT1 ADCY10
25
Show member pathways
12.96 MAPK1 JUN ITGB2 GNAI1 GNA15 GNA14
26
Show member pathways
12.91 TLR4 MAPK1 JUN CCL5 AKT1
27
Show member pathways
12.85 MAPK1 JUN ITGB2 GNAZ GNAI1 GNA15
28
Show member pathways
12.84 OPRM1 MAPK1 GNAQ GNAI1 GNA15 GNA14
29
Show member pathways
12.84 MAPK1 JUN ITGB2 GNAZ GNAQ GNAI1
30
Show member pathways
12.8 MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
31 12.78 AKT1 CCL2 CCL5 EGF ITGB2 JUN
32
Show member pathways
12.77 MAPK1 GNAZ GNAI1 GNA15 GNA14 EGF
33
Show member pathways
12.76 MAPK1 JUN GNAI1 GNA15 GNA14 CXCR4
34
Show member pathways
12.74 TLR4 MAPK1 JUN CCL2 AKT1
35
Show member pathways
12.74 MAPK1 JUN EGF CXCR4 AKT1
36
Show member pathways
12.74 MAPK1 JUN GNAZ GNAI1 GNA15 EGF
37
Show member pathways
12.71 MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
38
Show member pathways
12.7 TLR4 MAPK1 JUN GNAQ AKT1
39
Show member pathways
12.69 GNAZ GNAQ GNAI1 EGF ADCY10
40
Show member pathways
12.58 JUN GNAZ GNAQ GNAI1
41
Show member pathways
12.58 OPRM1 MAPK1 GNAQ GNAI1 GNA15 GNA14
42
Show member pathways
12.57 GNAZ GNAI1 GNA15 GNA14 AKT1
43
Show member pathways
12.56 MAPK1 JUN EGF AKT1
44
Show member pathways
12.55 GNAQ GNAI1 GNA15 GNA14
45
Show member pathways
12.53 TLR4 MAPK1 JUN EGF AKT1
46
Show member pathways
12.52 MAPK1 JUN EGF AKT1
47
Show member pathways
12.49 MAPK1 GNAZ GNAI1 GNA15 GNA14 CXCR4
48 12.49 MAPK1 JUN GNAZ GNAI1 GNA15 GNA14
49 12.47 MAPK1 JUN EGF AKT1
50
Show member pathways
12.46 MAPK1 JUN CCL2 AKT1

GO Terms for Pertussis

Cellular components related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heterotrimeric G-protein complex GO:0005834 9.32 GNAZ GNAQ GNAI1 GNA15 GNA14

Biological processes related to Pertussis according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.21 CCL11 CCL2 CCL5 JUN OPRM1 TLR4
2 inflammatory response GO:0006954 10.21 TLR4 ITGB2 FPR1 CXCR4 CCL5 CCL2
3 cellular response to tumor necrosis factor GO:0071356 10.18 MAPK1 CCL5 CCL2 CCL11 AKT1
4 cellular response to type II interferon GO:0071346 10.17 TLR4 CCL5 CCL2 CCL11
5 neutrophil chemotaxis GO:0030593 10.16 ITGB2 CCL5 CCL2 CCL11
6 positive regulation of endothelial cell proliferation GO:0001938 10.15 AKT1 CCL11 EGF JUN
7 chemotaxis GO:0006935 10.11 MAPK1 FPR1 CXCR4 CCL5 CCL2 CCL11
8 ERK1 and ERK2 cascade GO:0070371 10.1 CCL11 EGF MAPK1 TLR4
9 protein kinase B signaling GO:0043491 10.08 CCL5 CCL2 AKT1
10 monocyte chemotaxis GO:0002548 10.08 CCL5 CCL2 CCL11
11 chemokine-mediated signaling pathway GO:0070098 10.08 CXCR4 CCL5 CCL2 CCL11
12 cellular response to reactive oxygen species GO:0034614 10.07 MAPK1 JUN AKT1
13 cellular response to cadmium ion GO:0071276 10.06 MAPK1 JUN AKT1
14 lymphocyte chemotaxis GO:0048247 10.05 CCL11 CCL2 CCL5
15 lipopolysaccharide-mediated signaling pathway GO:0031663 10.02 AKT1 CCL2 CCL5 MAPK1 TLR4
16 eosinophil chemotaxis GO:0048245 10 CCL5 CCL2 CCL11
17 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 10 OPRM1 GNAZ GNAI1 ADORA1
18 signal transduction GO:0007165 10 ADORA1 AKT1 CCL11 CCL2 CCL5 CXCR4
19 action potential GO:0001508 9.99 GNAQ GNA15 GNA14
20 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.93 FPR1 GNA14 GNA15 GNAI1 GNAQ GNAZ
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 TLR4 OPRM1 ITGB2 AKT1
22 G protein-coupled receptor signaling pathway GO:0007186 9.7 SST OPRM1 GNAZ GNAQ GNAI1 GNA15

Molecular functions related to Pertussis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor binding GO:0001664 10 ADORA1 FPR1 GNA14 GNA15 GNAI1 GNAQ
2 nucleotide binding GO:0000166 9.97 MAPK1 GNAZ GNAQ GNAI1 GNA15 GNA14
3 chemokine activity GO:0008009 9.88 CCL5 CCL2 CCL11
4 CCR chemokine receptor binding GO:0048020 9.73 CCL5 CCL2 CCL11
5 G protein-coupled serotonin receptor binding GO:0031821 9.62 GNAZ GNAI1
6 G-protein beta/gamma-subunit complex binding GO:0031683 9.4 GNAZ GNAQ GNAI1 GNA15 GNA14 ADORA1
7 guanyl nucleotide binding GO:0019001 9.35 GNAZ GNAQ GNAI1 GNA15 GNA14

Sources for Pertussis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....